Carteyva receives IND approval for clinical trial in second-line large b-cell lymphoma

pharmafile | March 31, 2022 | News story | Business Services  

An investigational new drug (IND) clearance from the National Medical Products Administration (NMPA) of China, for a pivotal clinical trial of anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product, Carteyva. This is for the treatment of second-line large B-cell lymphoma.

B-cell lymphoma is a group of malignant B-cell monoclonal amplified heterogeneous malignancies, accounting for approximately 85% of non-Hodgkin lymphoma (NHL). Large B-cell lymphoma (LBCL) is the most common subtype of NHL worldwide, accounting for 35% to 50% of all newly diagnosed cases in China. 50% of patients could be cured by current standard of care (R-CHOP) chemotherapy.

JW Therapeutics conducted this multi-centre, randomised, open label Phase III study to compare the efficacy and safety of Carteyva to standard second-line therapy in adult subjects with relapse/refractory large B-cell lymphoma, not reaching complete response (CR) after first-line therapies or relapsed within 12 months of CR.

Relmacabtagene autoleucel injection (Carteyva) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics. In September 2021, relma-cel was approved by the NMPA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, making it the first CAR-T product approved as Category 1 biology products in China.

JW Therapeutics is an independent and innovative biotechnology company, focusing on the development, manufacturing, and commercialising cell immunotherapy products.

Lina Adams

Related Content

No items found

Latest content